These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 38755541

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
    Alsaadi T, Noori S, Varakian R, Youssef S, Almadani A.
    BMC Neurol; 2022 Jun 16; 22(1):221. PubMed ID: 35710354
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Filling the data gap on CGRP mAb therapy in low- to middle-income countries in Southeast Asia: insights from a real-world study in Thailand.
    Anukoolwittaya P, Hiransuthikul A, Pongpitakmetha T, Thanprasertsuk S, Rattanawong W.
    J Headache Pain; 2024 Sep 12; 25(1):150. PubMed ID: 39267011
    [Abstract] [Full Text] [Related]

  • 26. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine.
    Driessen MT, Cohen JM, Thompson SF, Patterson-Lomba O, Seminerio MJ, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R.
    J Headache Pain; 2022 May 16; 23(1):56. PubMed ID: 35578182
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Persistence, effectiveness, and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies in patients with chronic migraine.
    de Dios A, Pagès-Puigdemont N, Ojeda S, Riera P, Pelegrín R, Morollon N, Belvís R, Real J, Masip M.
    Headache; 2024 Sep 13. PubMed ID: 39268992
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience.
    Raffaelli B, Terhart M, Mecklenburg J, Neeb L, Overeem LH, Siebert A, Steinicke M, Reuter U.
    J Headache Pain; 2022 Mar 30; 23(1):40. PubMed ID: 35350990
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC, Schwedt TJ.
    Prog Brain Res; 2020 Mar 30; 255():143-170. PubMed ID: 33008505
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
    Zhou Z, Urman R, Gill K, Park AS, Vuvu F, Patel LB, Lu J, Wade RL, Frerichs L, Bensink ME.
    J Headache Pain; 2023 Nov 09; 24(1):153. PubMed ID: 37946113
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.